Semaglutide Weight Management and Cardiovascular Risk Reduction slide image

Semaglutide Weight Management and Cardiovascular Risk Reduction

Investor contact information Share information Novo Nordisk's B shares are listed on the stock exchange in Copenhagen under the symbol 'NOVO B'. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For further company information, visit Novo Nordisk on: www.novonordisk.com Novo Nordisk A/S Investor Relations Novo Alle 1 DK-2880 Bagsværd Investor Relations contacts Daniel Muusmann Bohsen David Heiberg Landsted Jacob Martin Wiborg Rode Mark Joseph Root (USA) +45 3075 2175 +45 3077 6915 +45 3075 5956 +1 848 213 3219 [email protected] [email protected] [email protected] [email protected] 10 August 2023 Upcoming events Financial statement for the first six months of 2023 02 November 2023 Financial statement for the first nine months of 2023 31 January 2024 Financial statement 2023
View entire presentation